Brief: IGC Pharma Announces Positive Interim Results For IGC-AD1 In Reducing Alzheimer’S Agitation
26/04/2024 16:18
April 26 (Reuters) - IGC Pharma Inc IGC.A :
* IGC PHARMA INC- ANNOUNCES POSITIVE INTERIM RESULTS FOR
IGC-AD1
IN REDUCING ALZHEIMER’S AGITATION
* IGC PHARMA INC- RESULTS INDICATE THAT IGC-AD1 CLINICALLY
REDUCED AGITATION COMPARED TO PLACEBO
Source text for Eikon: ID:
Further company coverage: IGC.A
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment